Literature DB >> 8816019

Management of Bell's palsy.

M A Jabor1, G Gianoli.   

Abstract

Bell's palsy or idiopathic palsy is the most common disorder affecting the facial nerve. Diagnosis is primarily one of exclusion. There is typically an acute unilateral facial paresis that evolves in 24 to 48 hours. Etiology and pathophysiology are heavily disputed, and as of yet unknown. The natural history of Bell's palsy is favorable. Eight-four percent show satisfactory recovery without any treatment, however 16% suffer moderate to severe sequelae. Prognosis is influenced by degree of paresis, age of patient, and time until first signs of recovery. Prognostic testing currently involves various electrophysiological tests. More than 90% degeneration of the facial nerve carries a poor prognosis for recovery; these are the patients who may benefit from facial nerve decompression surgery. If surgery is performed it should be done early (< 21 days from onset of palsy) and should include a middle cranial fossa decompression. Steroids are generally agreed to be beneficial. Acyclovir would seem to be a promising drug; however studies have not adequately assessed its use.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8816019

Source DB:  PubMed          Journal:  J La State Med Soc        ISSN: 0024-6921


  4 in total

Review 1.  Acupuncture for Bell's palsy.

Authors:  Ning Chen; Muke Zhou; Li He; Dong Zhou; N Li
Journal:  Cochrane Database Syst Rev       Date:  2010-08-04

2.  Facial paralysis for the plastic surgeon.

Authors:  Aaron M Kosins; Keith A Hurvitz; Gregory Rd Evans; Garrett A Wirth
Journal:  Can J Plast Surg       Date:  2007

Review 3.  The neurologist's dilemma: a comprehensive clinical review of Bell's palsy, with emphasis on current management trends.

Authors:  Anthony Zandian; Stephen Osiro; Ryan Hudson; Irfan M Ali; Petru Matusz; Shane R Tubbs; Marios Loukas
Journal:  Med Sci Monit       Date:  2014-01-20

4.  Herbal medicine for treating Bell's palsy: A retrospective chart review.

Authors:  Dong-Eun Jin; Soo-Young Jang; Yu-Sun Jung; Gyu-Ho Choi; Hyeon-Cheol Shin
Journal:  Integr Med Res       Date:  2020-04-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.